Last Week in Cannabis #1
August 3–9, 2026 | Issue #1
Hey friend — welcome to the very first Last Week in Cannabis on Ask Mary Jane. Every Monday I'll round up the most interesting things that happened in the cannabis world the week before, and break them down in plain language. No industry jargon, no overwhelm — just what's actually going on, and why it might matter to you. Let's get into it.
1. NEW RESEARCH — Legalizing Cannabis Did Not Increase Youth Hospitalizations, Study Finds
Researchers published a study this week in the International Journal of Population Data Science examining cannabis-related hospitalizations among children and teenagers over a ten-year period — covering five years before cannabis legalization and five years after. The study found that legalizing marijuana did not lead to a notable increase in cannabis-related hospitalizations among children and teenagers. Hospitalization rates before legalization, during the initial phase, and during the second phase remained essentially flat, showing no meaningful upward trend.
Mary Jane's Take: This is important research, and it adds to a growing pile of evidence that legalization — done properly — does not automatically put young people at greater risk. One of the most common fears raised by opponents of cannabis legalization is that it will harm children. A decade of real hospitalization records does not support that fear. That does not mean parents should be complacent about keeping cannabis products safely stored away from children — that remains critical. But it does mean the conversation around legalization and youth safety deserves to be grounded in actual data, not assumptions.
2. UNITED STATES — The Senate Just Delayed a Federal Hemp THC Ban Until December
Hemp-derived THC products — drinks, gummies, and vapes made from hemp rather than cannabis — have been in regulatory limbo in the United States for years. A ban was set to take effect in November, but the US Senate passed a bipartisan funding bill on August 8th that delays the planned ban on most hemp-derived THC products from November 12th to December 11th. The Senate rejected an attempt to keep the original November timeline, by a vote of 61-32. The bill still requires House approval and the president's signature.
The delay is intended to give lawmakers more time to develop a proper regulatory framework for the $28 billion hemp industry rather than banning it outright.
Mary Jane's Take: This is a temporary reprieve, not a solution. The debate is genuinely complicated: some lawmakers want these products banned because they are accessible to minors and sold without consistent safety standards. Others argue that prohibition of a massive industry, without a regulatory alternative ready to go, creates more problems than it solves. December is not far away. This is one of the bigger regulatory stories in the cannabis world right now, and it will keep developing.
3. GLOBAL — CBD Provided Pain Relief Comparable to Codeine After Laser Eye Surgery, Clinical Trial Finds
A clinical trial published this week found that CBD provided pain relief comparable to a standard codeine-acetaminophen combination following laser eye surgery — one of the more reliably painful common outpatient procedures. Researchers described the results as promising for the potential use of CBD as a non-opioid pain management option in post-surgical settings.
Mary Jane's Take: Studies like this matter for a few reasons. First, they add to the growing body of clinical evidence around CBD's real-world medical applications — this is a controlled trial on actual surgical patients, not a preliminary lab study. Second, any credible alternative to opioids for post-operative pain is worth paying close attention to. Opioid dependence often begins with a legitimate prescription after a procedure. A cannabinoid-based option that performs as well and carries a very different risk profile is exactly the kind of research the medical world needs more of.
4. GLOBAL — The FAA Is Rethinking Cannabis Rules for Pilots
Following the US federal government's rescheduling of medical cannabis earlier this year, the Federal Aviation Administration announced it is working with the National Academies of Sciences, Engineering, and Medicine to develop updated fitness-for-duty standards for pilots and air traffic controllers around cannabis use. The current FAA rules require pilots to disclose cannabis use and prohibit flying while impaired, but the rescheduling decision has prompted a formal review of how the agency treats cannabis relative to other medications.
Mary Jane's Take: Aviation is one of the most safety-sensitive environments imaginable, so it makes sense that the FAA is being deliberate here. What's notable is that rescheduling cannabis — even just for medical use — is already creating ripple effects across industries and regulators that have long treated cannabis as categorically different from other substances. The question of how to assess cannabis-related impairment in safety-critical roles is one that every sector is going to need to grapple with as the regulatory landscape shifts.
That's your first week together — two international stories, two global ones. I'll be here every Monday. See you next week.
— Mary Jane
